Next-Generation VNS System and Implantable Device Approved


LivaNova has received FDA approval for its next-generation Vagus Nerve Stimulation (VNS) Therapy Programming System for drug-resistant epilepsy. The FDA has also approved the company's SenTiva implantable device, the smallest and lightest responsive therapy for epilepsy. The new VNS Therapy system features a wireless wand and new user interface on a small tablet, while the SenTiva device includes detect-and-respond mode designed to prevent seizures before they start and automatically deliver extra therapy to stop them if they do. The device also collects and logs events commonly associated with seizures, including a patient’s body position and heart rate variations. When the new VNS system andSenTiva are combined, physicians can utilize advanced options, such as guided and scheduled programming. The VNS Therapy Programming System is also compatibly with all LivaNova legacy VNS Therapy generators, allowing physicians to use the system with numerous patients.


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.